2022 AUA preview: Dr. Krambeck on top research in BPH and urinary stones
Amy Krambeck, MD, highlights 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting.
EP: 1.2022 AUA preview: Dr. Pearlman on top research in sexual dysfunction and infertility
EP: 2.2022 AUA preview: Dr. Krambeck on top research in BPH and urinary stones
EP: 3.2022 AUA preview: Dr. Almassi on top research in bladder cancer
EP: 4.2022 AUA preview: Dr. Schwen on top research in prostate cancer
In this video, Amy Krambeck, MD, discusses 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting. Krambeck is a professor of Urology, Department of Urology, Northwestern University, Feinberg School of Medicine.
The following 6 abstracts are previewed:
1. LBA01-02 (Morsy, et al):Efficacy of Low-Power Thulium Laser Enucleation of Prostate Larger Than 80 Grams
2. LBA01-05 (Beltran, et al):Surgical Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement By Holmium Laser Enucleation of the Prostate Versus Transurethral Resection of the Prostate And Open Adenomectomy
3. LBA01-06 (Amparore, el):Long Term Follow-Up of an International Multicenter Prospective Study in Application of Temporary Implantable Nitinol Device (iTind) in Men With Lower Urinary Tract Symptoms for BPH
4. LBA02-04 (Yang, et al): Effect of Extracorporeal Shock Wave Lithotripsy Combined With Extracorporeal Physical Vibration Lithotripsy in the Treatment of Patients With Ureteral Calculi
5. LBA02-08 (Harper, et al): Risk Factors for Increased Stent-Associated Symptoms Following Ureteroscopy for Urinary Stones: Results From the Urinary Stone Disease Research Network (USDRN) Stents Study
6. LBA02-10 (Mookerji, et al): Assessing the Risks of A Positive Urine Culture in Uncomplicated Renal Colic Patients
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).
